Payment overview · 2025
General Payments
$364.64
10 reported records · 7 companies
Healthcare provider profile · identity verified
Mansour Mofidi, DO
Allopathic & Osteopathic Physicians|Internal Medicine · LA MESA, CA · NPI 1164598843
Verified facts
What the public records show
CMS Open Payments records show Mansour Mofidi, DO received $364.64 in general payments during 2025 across 10 reported records.
MicroTransponder, Inc. accounted for 34.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $126.03 | 34.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $88.02 | 24.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.71 | 16.1% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $35.05 | 9.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.73 | 6.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.82 | 4.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.28 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $364.64 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $88.02 | 3 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $58.71 | 2 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $58.71 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $35.05 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $29.64 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $29.07 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 433 | 115 |
| Eliquis | Apixaban | 355 | 65 |
| Gabapentin | Gabapentin | 314 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 299 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 180 | 61 |
| Furosemide | Furosemide | 177 | 46 |
| Trazodone Hcl | Trazodone Hcl | 172 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 38 |
| Famotidine | Famotidine | 165 | 44 |
| Metformin Hcl | Metformin Hcl | 164 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 43 |
| Lisinopril | Lisinopril | 141 | 33 |
| Potassium Chloride | Potassium Chloride | 116 | 41 |
| Levetiracetam | Levetiracetam | 113 | 21 |
| Losartan Potassium | Losartan Potassium | 109 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 95 | 21 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 89 | 40 |
| Jardiance | Empagliflozin | 86 | 15 |
| Omeprazole | Omeprazole | 83 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 23 |
| Buspirone Hcl | Buspirone Hcl | 78 | 21 |
| Carvedilol | Carvedilol | 78 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 22 |
| Lorazepam | Lorazepam | 76 | 17 |
| Bumetanide | Bumetanide | 73 | 22 |
| Divalproex Sodium | Divalproex Sodium | 73 | 13 |
| Donepezil Hcl | Donepezil Hcl | 68 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 14 |
| Latanoprost | Latanoprost | 62 | 20 |
| Entresto | Sacubitril/Valsartan | 60 | 11 |
| Xarelto | Rivaroxaban | 59 | 12 |
| Memantine Hcl | Memantine Hcl | 57 | 12 |
| Prednisone | Prednisone | 53 | 16 |
| Mirtazapine | Mirtazapine | 51 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 50 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 21 |
| Baclofen | Baclofen | 48 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | 11 |
| Midodrine Hcl | Midodrine Hcl | 47 | 16 |
| Spironolactone | Spironolactone | 47 | 14 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | 15 |
| Sertraline Hcl | Sertraline Hcl | 41 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Allopurinol | Allopurinol | 35 | 12 |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Lactulose | Lactulose | 35 | 14 |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Ranolazine Er | Ranolazine | 35 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Lubiprostone | Lubiprostone | 32 | suppressed |
| Simvastatin | Simvastatin | 32 | 11 |
| Hydrocortisone | Hydrocortisone | 31 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 31 | 20 |
| Topiramate | Topiramate | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 17 |
| Clozapine | Clozapine | 27 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Folic Acid | Folic Acid | 26 | 11 |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | 13 |
| Insulin Lispro | Insulin Lispro | 25 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Humalog | Insulin Lispro | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 15 |
| Finasteride | Finasteride | 23 | 11 |
| Nystatin | Nystatin | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Xifaxan | Rifaximin | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 16 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 15 | 12 |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Epogen | Epoetin Alfa | 11 | suppressed |
| Insulin Aspart | Insulin Aspart | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Levocarnitine | Levocarnitine | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $364.64 · 10 records | MicroTransponder, Inc. | AVYCAZ, DALVANCE, DUPIXENT, EMBLAVEO, OFEV, Repatha, TEFLARO, TRELEGY ELLIPTA, VOWST | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error